Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.98 HKD | +2.80% | -2.38% | +4.49% |
Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.49% | 603M | |
+30.38% | 684B | |
+29.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.06% | 240B | |
+9.25% | 208B | |
-7.28% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- 1477 Stock
- News Ocumension Therapeutics
- Ocumension Therapeutics' Eye Drug Completes Clinical Trials, to Apply for NDA Soon